Methotrexate is an anti-rheumatic agent used as a first-line tretment for rheumatoid arthritis. Hematological malignancies like lymphoma or acute myeloid leukemia have been reported to be secondary to treatment with Methotrexate, but are very uncommon. We report here the first Moroccan case of RA patient on low dose MTX, who developed AML. We also reviewed all similar cases.

Full-Text [PDF 406 kb]   (4386 Downloads)